Cite
HARVARD Citation
Zucali, P. et al. (2022). Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study. Journal for immunotherapy of cancer. 10 (1), p. . [Online].